FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912444456> ?p ?o ?g. }

• W2912444456 endingPage "S410" @default.
• W2912444456 startingPage "S409" @default.
• W2912444456 abstract "From the PURSUIT programme, it is known that golimumab (GLM) trough concentrations (TC) >2.5 mg/l at week (w)6 of induction therapy are associated with clinical response in patients with ulcerative colitis (UC).1 No TC threshold has been established for mucosal healing (MH; Mayo endoscopic score ≤1). A population pharmacokinetic (popPK) model may support dose optimisation to improve attainment of a predefined TC target. GLM concentration–time data of 56 patients with UC (335 venepuncture and 296 dried bloodspot (DBS) samples) were obtained from 2 study centres (University Hospitals Leuven, Belgium and Ljubljana University Medical Centre, Slovenia).2,3 A popPK model was developed using NONMEM 7.4. Exposure during GLM induction therapy was linked to MH at w14. A two-compartment popPK model with linear absorption and elimination showed good predictive capacity (Figure 1A). The estimated popPK parameters (typical value [%RSE]) were absorption constant (0.511 day−1 [8%]), apparent clearance CL/F (0.407 l/day [6%]), volume of distribution in the central compartment (9.16 l [5%]) and peripheral compartment Vp/F (3.21 l [22%]) and inter-compartmental clearance (0.464 l/day [13%]). Antibodies to GLM and higher alkaline phosphatase increased GLM CL/F, while prior biological use was associated with a larger Vp/F, all predicting lower GLM exposure. Still, 48% and 147% of the interindividual variability (IIV) on CL/F and Vp/F remained unexplained. A total of 14/40 patients (35%, 16/56 no endoscopy data available) achieved MH after GLM induction therapy. These patients had higher model-predicted GLM TC at w6 (median 7.6 mg/l, interquartile range [5.8–8.0]) compared with patients not achieving MH (4.7 mg/l [3.3–6.8]) (p = 0.005). A GLM TC threshold at w6 >7.4 mg/l predicted MH (Figure 1B). In addition, the estimated area under the GLM concentration–time curve (AUC) from w0 to w6 was higher when MH was achieved (p = 0.010). With the currently approved induction dosing of GLM, only 10/40 (25%) reached the proposed 7.4 mg/l TC target at w6, suggesting underexposure in a substantial proportion of patients. This popPK model shows good predictive capacity and may be implemented in a therapeutic drug monitoring software tool to allow better targeting of the here established exposure targets (TC and AUC) in individual patients. Still, Bayesian updating of individuals’ PK parameters using early DBS samples is recommended given the remaining large IIV. (A) Prediction-corrected visual predictive check. (B) Density plot and receiver-operating characteristic (ROC) curve of pGLM TC at w6 as a predictor of MH at w14. References 1. Adedokun OJ, Xu Z, Marano CW, et al. Pharmacokinetics and exposure–response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from Phase 2/3 PURSUIT induction and maintenance studies. J Crohns Colitis 2017;11:35–46. 2. Detrez I, Dreesen E, Van Assche G, et al. Golimumab dried blood spot analysis (GOUDA): A prospective trial to validate golimumab concentration analysis using the dried blood spot methodology. Inflamm Bowel Dis 2018; P431. 3. Stefanovic S, Detrez I, Compernolle G, et al. Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitis. Inflamm Bowel Dis 2018; P632." @default.
• W2912444456 created "2019-02-21" @default.
• W2912444456 creator A5006600034 @default.
• W2912444456 creator A5018425502 @default.
• W2912444456 creator A5019474609 @default.
• W2912444456 creator A5024846292 @default.
• W2912444456 creator A5029428855 @default.
• W2912444456 creator A5033719787 @default.
• W2912444456 creator A5057103448 @default.
• W2912444456 creator A5082317019 @default.
• W2912444456 date "2019-01-25" @default.
• W2912444456 modified "2023-10-15" @default.
• W2912444456 title "P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis" @default.
• W2912444456 doi "https://doi.org/10.1093/ecco-jcc/jjy222.713" @default.
• W2912444456 hasPublicationYear "2019" @default.
• W2912444456 type Work @default.
• W2912444456 sameAs 2912444456 @default.
• W2912444456 citedByCount "1" @default.
• W2912444456 countsByYear W29124444562019 @default.
• W2912444456 crossrefType "journal-article" @default.
• W2912444456 hasAuthorship W2912444456A5006600034 @default.
• W2912444456 hasAuthorship W2912444456A5018425502 @default.
• W2912444456 hasAuthorship W2912444456A5019474609 @default.
• W2912444456 hasAuthorship W2912444456A5024846292 @default.
• W2912444456 hasAuthorship W2912444456A5029428855 @default.
• W2912444456 hasAuthorship W2912444456A5033719787 @default.
• W2912444456 hasAuthorship W2912444456A5057103448 @default.
• W2912444456 hasAuthorship W2912444456A5082317019 @default.
• W2912444456 hasBestOaLocation W29124444561 @default.
• W2912444456 hasConcept C112705442 @default.
• W2912444456 hasConcept C126322002 @default.
• W2912444456 hasConcept C139254425 @default.
• W2912444456 hasConcept C141071460 @default.
• W2912444456 hasConcept C2776239304 @default.
• W2912444456 hasConcept C2776694085 @default.
• W2912444456 hasConcept C2777138892 @default.
• W2912444456 hasConcept C2779134260 @default.
• W2912444456 hasConcept C2780479503 @default.
• W2912444456 hasConcept C2781290027 @default.
• W2912444456 hasConcept C2908647359 @default.
• W2912444456 hasConcept C2991767035 @default.
• W2912444456 hasConcept C71924100 @default.
• W2912444456 hasConcept C90924648 @default.
• W2912444456 hasConcept C99454951 @default.
• W2912444456 hasConceptScore W2912444456C112705442 @default.
• W2912444456 hasConceptScore W2912444456C126322002 @default.
• W2912444456 hasConceptScore W2912444456C139254425 @default.
• W2912444456 hasConceptScore W2912444456C141071460 @default.
• W2912444456 hasConceptScore W2912444456C2776239304 @default.
• W2912444456 hasConceptScore W2912444456C2776694085 @default.
• W2912444456 hasConceptScore W2912444456C2777138892 @default.
• W2912444456 hasConceptScore W2912444456C2779134260 @default.
• W2912444456 hasConceptScore W2912444456C2780479503 @default.
• W2912444456 hasConceptScore W2912444456C2781290027 @default.
• W2912444456 hasConceptScore W2912444456C2908647359 @default.
• W2912444456 hasConceptScore W2912444456C2991767035 @default.
• W2912444456 hasConceptScore W2912444456C71924100 @default.
• W2912444456 hasConceptScore W2912444456C90924648 @default.
• W2912444456 hasConceptScore W2912444456C99454951 @default.
• W2912444456 hasIssue "Supplement_1" @default.
• W2912444456 hasLocation W29124444561 @default.
• W2912444456 hasOpenAccess W2912444456 @default.
• W2912444456 hasPrimaryLocation W29124444561 @default.
• W2912444456 hasRelatedWork W10390674 @default.
• W2912444456 hasRelatedWork W1989677012 @default.
• W2912444456 hasRelatedWork W2021574530 @default.
• W2912444456 hasRelatedWork W2087821742 @default.
• W2912444456 hasRelatedWork W2104998353 @default.
• W2912444456 hasRelatedWork W2123003250 @default.
• W2912444456 hasRelatedWork W2158131108 @default.
• W2912444456 hasRelatedWork W2365331627 @default.
• W2912444456 hasRelatedWork W2397635577 @default.
• W2912444456 hasRelatedWork W4285256702 @default.
• W2912444456 hasVolume "13" @default.
• W2912444456 isParatext "false" @default.
• W2912444456 isRetracted "false" @default.
• W2912444456 magId "2912444456" @default.
• W2912444456 workType "article" @default.